• Reliable Cell Assays with Poly(I:C), a Synthetic dsRNA Analo

  2026-04-30

  This article addresses persistent laboratory challenges in cell viability, proliferation, and cytotoxicity assays by showcasing the validated performance of Poly(I:C), a synthetic double-stranded RNA (dsRNA) analog and Toll-like receptor 3 (TLR3) agonist (SKU B5551). Drawing on quantitative evidence and scenario-driven Q&A, the discussion guides biomedical researchers in optimizing innate immune response stimulation and dendritic cell maturation workflows with APExBIO’s Poly(I:C).

• Epalrestat as a Metabolic Modulator: Beyond Diabetic Models

  2026-04-30

  Explore Epalrestat’s role as an aldose reductase inhibitor not only in diabetic neuropathy research but also as a strategic tool for dissecting cancer metabolism and oxidative stress. This article uniquely connects polyol pathway inhibition to practical decisions in advanced disease modeling.

• Ampicillin Sodium: Mechanism, Benchmarks & Workflow Integrat

  2026-04-29

  Ampicillin sodium is a β-lactam antibiotic that acts as a competitive transpeptidase inhibitor, disrupting bacterial cell wall biosynthesis and exhibiting potent antibacterial activity. This article details its molecular mechanism, quantitative efficacy, and best practices for research workflows. APExBIO’s high-purity Ampicillin sodium supports reproducible results in antibacterial activity assays and recombinant protein applications.

• Fulvestrant (ICI 182,780): Beyond ER Antagonism in Breast Ca

  2026-04-29

  Discover how Fulvestrant (ICI 182,780) advances research in ER-positive breast cancer by enabling post-translational MDM2 regulation and immune modulation. This in-depth review explores novel mechanistic insights and practical assay decision points, setting it apart from standard protocol guides.

• Oligomycin A as a Mitochondrial ATP Synthase Inhibitor: Prec

  2026-04-28

  Oligomycin A delivers unmatched specificity for dissecting mitochondrial ATP production and metabolic adaptation, empowering advanced workflows in cancer metabolism and apoptosis pathway studies. This article details optimized protocols, troubleshooting strategies, and the translational edge provided by APExBIO’s Oligomycin A in high-impact mitochondrial research.

• Capture-and-Release Strategy Boosts LFA Sensitivity via Ampl

  2026-04-28

  This study introduces the AmpliFold capture-and-release workflow, significantly enhancing the sensitivity of lateral flow assays (LFAs) through triggered rebinding mechanisms. The approach leverages cleavable linkers and optimized bioconjugation to overcome traditional kinetic limitations, offering up to 16-fold sensitivity improvements and practical advances for point-of-care testing.

• Thymosin-β4 Drives Angiogenesis in CLI via Notch/NF-κB Pathw

  2026-04-27

  This study demonstrates that thymosin-β4 (Tβ4) enhances angiogenesis and cell viability in a mouse model of critical limb ischemia (CLI) through the coordinated activation of Notch and NF-κB signaling. The findings illuminate a mechanistic pathway for therapeutic neovascularization in CLI, supported by robust in vitro and in vivo evidence.

• YC-1 in Translational Cancer Research: Beyond HIF-1α Inhibit

  2026-04-27

  Explore how YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol advances cancer research beyond conventional HIF-1α inhibition. This article reveals new mechanistic and translational insights, uniquely linking tumor hypoxia, angiogenesis, and neuroinflammatory pathways.

• Substance P (B6620): Protocol Guidance for CNS Research

  2026-04-26

  Substance P (SKU B6620) addresses the need for reliable tachykinin neuropeptide standards in studies on pain transmission, neuroinflammation, and immune response modulation. Its defined physicochemical properties and high purity enable reproducible CNS signaling assays, but use is strictly limited to research workflows and not suitable for diagnostic or clinical applications.

• CENPI Drives Breast Cancer Progression via Wnt/β-Catenin Pat

  2026-04-25

  Wu et al. (2025) identify centromere protein I (CENPI) as a key oncogenic driver in breast cancer, linking its overexpression to tumor progression and poor prognosis through modulation of the Wnt/β-catenin pathway. Their integrated approach, combining clinical data, cellular and animal models, and mechanistic assays, provides strong evidence positioning CENPI as a potential biomarker and therapeutic target.

• H 89 2HCl: Precision cAMP/PKA Pathway Inhibition in Cell Ass

  2026-04-24

  H 89 2HCl delivers unmatched selectivity for dissecting cAMP/PKA signaling, offering researchers a robust tool for modulating protein phosphorylation and cell differentiation. This guide details experimental workflows, troubleshooting tactics, and the latest insights from dopamine-regulated bone remodeling studies.

• Shufeng Xingbi Therapy: Modulating Th1/Th2 Balance and Gut F

  2026-04-24

  This study investigates how Shufeng Xingbi Therapy (SFXBT) affects Th1/Th2 immune balance and intestinal microbiota in an ovalbumin-induced allergic rhinitis rat model. Findings demonstrate that SFXBT alleviates nasal mucosal inflammation, shifts gut microbial composition, and downregulates key cytokines and transcription factors, offering mechanistic insight into its anti-allergic effects.

• Q-VD(OMe)-OPh: Advanced Caspase Inhibition for Apoptosis Ass

  2026-04-23

  Q-VD(OMe)-OPh stands out as a high-potency, low-cytotoxicity pan-caspase inhibitor, streamlining apoptosis research from cancer cell models to neuroprotection. Its workflow flexibility and robust performance, as illustrated in recent studies, empower researchers to precisely dissect cell death pathways and troubleshoot complex experimental setups.

• VX-765: Precision Caspase-1 Inhibition for Inflammation Mode

  2026-04-23

  VX-765 delivers unmatched selectivity for caspase-1, enabling rigorous dissection of IL-1β and IL-18-driven inflammation and pyroptosis. This article details advanced workflows, troubleshooting strategies, and translational insights empowered by VX-765, with a focus on blood-brain barrier repair and autoimmune research.

• Nitrocefin in Action: Unraveling β-Lactamase Diversity and R

  2026-04-22

  Explore Nitrocefin as a chromogenic cephalosporin substrate for advanced β-lactamase enzymatic activity measurement. This article delivers a deeper scientific lens on substrate specificity, cross-species resistance transfer, and modern assay optimization.

16201 records 1/1081 page Next 12345 下5页 Last page